Documento, Documento-Fibrosis HepáticaHCV patients with residual fibrosis after DAA treatment re‑establish their epigenetic signature after prolonged‑release pirfenidone: MINERVA study Mariana Ruiz / 14/10/2025
Documento, Documento-Fibrosis HepáticaPrevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis Mariana Ruiz / 12/08/2025
Documento, Documento-Fibrosis HepáticaEvaluación no invasiva de pirfenidona de liberación prolongada en cirrosis hepática compensada. Estudio ODISEA, un ensayo aleatorizado. Mariana Ruiz / 03/07/2025
Documento, Documento-Fibrosis HepáticaNoninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial Mariana Ruiz / 17/06/2025
Documento, Documento-Fibrosis HepáticaIdentifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care Mariana Ruiz / 16/04/2025
Documento, Documento-Fibrosis HepáticaGlobal prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Mariana Ruiz / 18/02/2025
Documento, Documento-Fibrosis HepáticaAssociation between elevated fibrosis-4 index of liver fibrosis and risk of hemorrhagic stroke Mariana Ruiz / 20/12/2024
Documento, Documento-Fibrosis HepáticaPirfenidona de liberación prolongada restaura la expresión de miRNAs y la metilación de islas CpG en pacientes con hepatitis C con respuesta viral sostenida y fibrosis hepática residual Mariana Ruiz / 21/10/2024
Documento, Documento-Fibrosis HepáticaMetabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study Mariana Ruiz / 25/08/2024
Documento, Documento-Fibrosis HepáticaHepatología clínica y trasplante hepático. Fascículo 1 bidi_Admin / 18/06/2024
Documento, Documento-Fibrosis HepáticaPredictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study Mariana Ruiz / 04/06/2024
Documento, Documento-Fibrosis HepáticaCirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico Mariana Ruiz / 06/05/2024
